Clinical trials: Oral Phase
Healthy Volunteers
A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers
This study aims to determine the proportion of study drug dacomitinib or PF-00299804, that is taken up from the digestive tract into the body when given as an oral tablet compared with that taken up by an intravenous dose.
- Trial name
- NCT01796327
- Testing
- dacomitinib oral, dacomitinib intravenous
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy…
- Trial name
- NCT06071442
- Testing
- Vemircopan, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Healthy
LEO 27847 - A Study in Healthy Male Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 27847 in healthy male subjects. The trial will be performed in two parts.
- Trial name
- NCT01007383
- Testing
- LEO 27847
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Healthy Volunteers
A Study of DZD2269 in Healthy Adult Participants
This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing.
- Trial name
- NCT04932005
- Testing
- DZD2269
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Lymphoid Malignancy, Solid Tumors
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
This is a randomized, single dose, open-label, multicenter crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase…
- Trial name
- NCT00982566
- Testing
- ABT-263
- Volunteers
- 37 people
- Sponsor
- AbbVie
Recurrent Neuroblastoma, Neuroblastoma
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Currently there is no known effective treatment for recurrent or resistant neuroblastoma. Fenretinide is an anticancer agent that may work differently than standard chemotherapy.
- Trial name
- SPOC2013-001 (NCT02163356)
- Testing
- Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- South Plains Oncology Consortium
Infertility
OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI
The primary objective of this study is to assess the increase in clinical pregnancy rate after administration of a range of single oral doses of OBE001, an oral oxytocin antagonist, compared to placebo.
- Trial name
- IMPLANT (NCT02310802)
- Testing
- OBE001 dose 1, OBE001 dose 2, OBE001 dose 3
- Where
- 18 sites in Belgium, Czechia and 4 more
- Volunteers
- 247 people
- Sponsor
- ObsEva SA
Advanced Breast Carcinoma, Advanced Colon Carcinoma
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have…
- Conditions
- Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04704661
- Testing
- Biopsy Procedure, Biospecimen Collection, Ceralasertib
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Head and Neck Neoplasms
Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
This is a Phase I multicenter, open-label, dose-escalation study of DTP348. DTP 348 is an oral dual drug with two mechanisms of action: 1.
- Trial name
- NCT02216669
- Testing
- DTP348
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Nocturnal Enuresis
Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
This is multi-center, randomized, placebo-controlled, parallel-group, double-blind, dose-escalating clinical trial designed to assess the efficacy and safety of desmopressin orally lyophilisate for the treatment of nocturnal…
- Trial name
- PNE (NCT01078753)
- Testing
- Desmopressin
- Where
- 15 sites in Japan
- Volunteers
- 89 people
- Sponsor
- Ferring Pharmaceuticals
Bacterial Infections
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults
This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult…
- Trial name
- NCT04578873
- Testing
- QPX7831
- Where
- 2 sites in United States, Australia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Periodontitis
Impact of Periodontal Therapy on Function and Quality of Life in Stage III Periodontitis
Stage III, Grade B periodontitis is a severe form of gum disease that damages the tissues and bone supporting the teeth. It can cause loose teeth, difficulty chewing, and reduced quality of life.
- Trial name
- NCT07450573
- Testing
- non-surgical periodontal treatment, surgical periodontal treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ankara Medipol University
Rheumatoid Arthritis
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking…
- Trial name
- NCT00556894
- Testing
- CF101
- Where
- 26 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 253 people
- Sponsor
- Can-Fite BioPharma
Arthritis, Rheumatoid
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
This double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of SKI-O-703 in healthy volunteers.
- Trial name
- NCT03315494
- Testing
- SKI-O-703 capsule
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Opioid Use Disorder
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
This study is open to people between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence.
- Trial name
- NCT06628622
- Testing
- BI 1356225
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Herpes Labialis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included.
- Trial name
- MATCH-1 (NCT04539483)
- Testing
- HDIT101 (blinded therapy), Photo documentation of orolabial herpes lesions, Completion of questionnaires (patient-reported outcomes)
- Where
- 5 sites in Germany
- Volunteers
- 761 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
HIV Infections
TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions
The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial…
- Trial name
- NCT01052883
- Testing
- DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Hereditary Angioedema, Hereditary Angioedema Type I
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks.
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
- Trial name
- RAPIDe-2 (NCT05396105)
- Testing
- deucrictibant
- Where
- 60 sites in United States, Argentina and 22 more
- Volunteers
- 150 people
- Sponsor
- Pharvaris Netherlands B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.